FSP 2023 Summer Pathology Conference


Join us at the FSP 2023 Summer Pathology Conference taking place on July 14-16, 2023 at the Eau Palm Beach Resort & Spa

The FSP 2023 Summer Pathology Conference will provide pathologists with education surrounding a wide range of topics and the opportunity to learn and adopt new strategies and tools to aid in the diagnosis and analysis of diseases. The conference will provide practical updates and clinical pearls and pitfalls in the following topics:


In addition, there will be education on additional topics during interactive read slides and microscopy sessions using an innovative digital platform. We are offering a new state mandated course on prevention of medical errors for pathologists on Friday, July 14 from 4:00 pm to 6:00 pm so make plans to join us early!


Personal Information

Contact Information

STATE MANDATED COURSE: Prevention of Medical Errors for Pathologists

New This Year - We are offering a new state mandated course on prevention of medical errors for pathologists on Friday, July 14 from 4:00 pm to 6:00 pm, so make plans to join us early!
Please indicate if you are planning on attending this session.

Registration Type

Proof of Training Status


Florida Society of Pathologists Terms & Conditions and Cancellation Policy

COVID 19 Policy:
By registering for the conference, sponsor agrees to adhere to all infectious disease protocols in place during the event, including those imposed by FSP, the venue, the county health department, and any state directives, and if sponsor fails, they consent to be ejected from the conference and the venue with no refund. By registering, sponsor accepts and assumes all risks of in-person participation, including the risk of injury or contracting an infectious disease, including but not limited to COVID-19 exposure.

Assumption of Risk:
I accept and assume all risks of my in-person participation, including the risk of injury or contracting an infectious disease, including but not limited to COVID-19 exposure.

Badge Information:
By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee's contact information with the company that scanned the conference badge.

Cancellation Policy:
A written notice of cancellation must be received by June 16, 2023 to receive a refund. Cancellations received prior to this date will be honored minus a $100 administration fee. Refunds will not be honored after June 16, 2023. Telephone cancellations cannot be accepted.

Special Needs
We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Please contact info@flpath.org at least four (4) weeks in advance prior to the event.

Communication, Confirmation and Receipts:
You must provide a valid Email address when you register online to receive a confirmation/receipt. Please remember to check your spam/junk box for confirmation emails and receipts.

You consent to the photographing and recording of your likeness and voice and the use of these photographs and/or recordings singularly or in conjunction with other photographs and/or recordings for advertising, publicity, commercial or other business purposes.

Florida Society of Pathologists COVID-19 Policy and Waiver of Liability

While participating in-person at the 2023 FSP Summer Conference on July 14-16, 2023, the FSP will follow suggested federal, state, and local preventive measures to reduce the spread of COVID-19; however, the FSP cannot guarantee that participants, attendees, exhibitors, vendors, staff, or others in attendance (“participants”) will not become infected with COVID-19. All participants will be asked to:

  1. Wear masks when and where required
  2. Practice social distancing when and where required
  3. Follow any pathway signage
  4. Follow good personal hygiene practices
  5. Practice self-monitoring & self-reporting
  6. Follow the requirements of the host hotel that are in place at the time of the meeting.
  7. Not travel to or attend the FSP meeting if you are sick or become sick
  8. Take reasonable precautions to ensure your own comfort

I understand the inherent risks of attending the FSP meeting and that I may be exposed to or infected by COVID-19. By attending the FSP meeting, I am acknowledging that exposure or infection may result in quarantine requirements, serious illness, permanent disability and/or death. I agree to follow all health and safety precautions for the FSP meeting. I also acknowledge that if I choose not to follow the health and safety precautions as outlined by the FSP, the meeting venue and other partners for the FSP, my registration may be canceled, and I may be removed from the meeting with no refund of any related expenses. I willingly agree to comply with the stated terms and conditions for participation as protection against COVID-19 including those outlined here for the FSP meeting.


Payment Information

Abstract Poster Submission #1
Poster Title
Author Name(s)
Financial Disclosures
Disclosure of Funding Support
Choose one of the following Topics


Justin Bishop, MD
Professor and Chief of Anatomic Pathology
UT Southwestern Medical Center
Dallas, TX
Topic: Head and Neck Pathology

Peter A. Humphrey, MD, PhD
Professor of Pathology
Director of Genitourinary Pathology
New Haven, CT
Topic: GU Pathology

Kamran M. Mirza, MD PhD
Associate Professor,
Vice-Chair of Education and Academic Affairs,
Program Director of Hematopathology fellowship,
Assistant Dean of DEI
Loyola University Chicago Stritch School of Medicine
Maywood, IL
Topic: Hematopathology

Victor G. Prieto, MD, PhD
Pathology chair
Univ of Texas – MD Anderson Cancer Center
Houston, TX
Topic: Dermatopathology

Prevention of Medical Errors Faculty

Susan Boisvert BSN, MHSA, DFASHRM
Senior Patient Safety Risk Manager
The Doctors Company
Jacksonville, FL
Topic: Prevention of Medical Errors


To view the presentation slides please log in to your account

Friday, July 14, 2023

3:00 pm - 6:00 pm
Registration Open   


4:00 pm - 6:00 pm
STATE MANDATED COURSE: Prevention of Medical Errors for Pathologists


Saturday, July 15, 2023

7:00 am - 7:00 pm
Registration Open   


7:00 am - 8:00 am
Breakfast with Exhibitors   


8:00 am - 8:15 am
Welcome and Introductions   


8:15 am - 9:15 am
New WHO classification of melanocytes lesions. Proposal of multiple melanoma
Victor G. Prieto, MD, PhD


9:15 am - 10:15 am
Update in cutaneous adnexal neoplasms
Victor G. Prieto, MD, PhD


10:15 am - 10:45 am
Refreshment Break with Exhibitors   


10:45 am - 11:45 am
Use of ancillary techniques applied to the diagnosis of melanocytic lesions Microscope Session
Victor G. Prieto, MD, PhD


11:45 am - 12:00 pm
FSP Business Meeting   


12:15 pm - 1:00 pm
Sponsored Lunch Session   


1:00 pm - 1:30 pm
Dessert Break with Exhibitors   


1:30 pm - 2:30 pm
Prostate Cancer Diagnosis and Grading: 2023 and 5th Edition WHO Update
Peter A. Humphrey, MD, PhD


2:30 pm - 3:15 pm
Interesting or unusual cases in hematopathology Microscopy Session
Kamran M. Mirza MD, PhD


3:15 pm - 3:45 pm
Refreshment Break with Exhibitors   


3:45 pm - 4:45 pm
Kidney Neoplasia: What is New in the 5th Edition WHO Classification
Peter A. Humphrey, MD, PhD


4:45 pm - 5:45 pm
Genitourinary Pathology: Variations of Histomorphological Presentation of Cancer Microscopy Slide Session
Peter A. Humphrey, MD, PhD


5:45 pm - 6:30 pm
Sponsored Session   


6:30 pm - 7:30 pm
Welcome Reception with Exhibitors   


Sunday, July 16, 2023

7:15 am - 12:15 pm
Registration Open   


7:30 am - 8:30 am
Breakfast with Exhibitors   


8:30 am - 9:30 am
WHO updates on the classification of Salivary Gland Tumors
Justin Bishop, MD


9:30 am - 10:30 am
WHO updates on the classification of Tumors of the Nasal Cavity, Paranasal and Skull Base
Justin Bishop, MD


10:30 am - 11:00 am
Refreshment Break with Exhibitors   


11:00 am - 12:00 pm
Head and Neck Pathology Microscopy Session
Justin Bishop, MD


12:00 pm - 12:15 pm
Closing Remarks   



The FSP 2023 Summer Pathology Conference will take place at the EAU Palm Beach.

Eau Palm Beach Resort & Spa
100 South Ocean Boulevard
Manalapan, Florida 33462
Phone: 561-533-6000

Visit Hotel Website

FSP attendees will receive a special room rate that starts at $319 per night, plus taxes. The group rate is guaranteed for reservations made on or before June 22, 2023 or until the room block is filled.



Accreditation Information




This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Florida Medical Association designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statements of credit/participation will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme . If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by July 26, 2023.


This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.

The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.


At the conclusion of this activity, all participants should be able to:

  • Review practical ramifications of the new 5th Edition WHO prostate cancer classification
  • Recognize the new and emerging renal neoplastic entities in the 2022 WHO 5th edition on Urinary and Male Genital Tumours
  • Recognize various pathologic and clinical features of Genitourinary tumors (K)
  • Review the most clinically relevant cutaneous adnexal neoplasms
  • Review the diagnosis and classification of melanocytic tumors
  • Describe the molecular characteristics associated with each melanocyte pathway, in particular those detected in spitzoid lesions
  • Review the use of molecular ancillary techniques applied to the diagnosis of melanocytic lesions
  • Review the updates to the 2022 WHO Classification of Tumors of the nasal cavity, paranasal and skull base and salivary gland tumors
  • List 2 new salivary gland tumors included in the new WHO classification
  • Describe the role of molecular testing in modern sinonasal tumor pathology
  • Describe a diagnostic approach to challenging head and neck tumor specimens that incorporates clinical, radiographic, histologic, immunophenotypic, and molecular data
  • Recognize diagnostic features and differential diagnosis in the evaluation of various hematologic disease lesions
  • Discuss evidence-based strategies to reduce the risk of medical error and improve patient safety



This activity is supported by an educational grant from AstraZeneca.




None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients except for Dr. Marilyn Bui who disclosed:

Grant/Research Support:

  • John Cleveland, PhD- Principal Investigator
  • Marusyk, PhD, Phillip Altrock, PhD, David Basanta, PhD- Co-Principal Investigator
  • Robert Gilles, PhD, Bethany Niell, MD, PhD- Co- Principal Investigator
  • Consultant/Advisor/Contractor:
    • 2019-2022 Scientific Advisory Board Member of ContextVision AB
    • 2020-Present Scientific Advisory Board Member of Aiforia Technologies Oy
    • 2020-2022 Scientific Advisory Board member of Visiopharm
    • 2020-2022 HER2-Low Pathology Advisory Board Member of AstraZeneca
    • Nov 13, 2020 RNA/GEP Scientific Advisory Board member of Foundation Medicine Institute
    • February-April 2021 Group leader of Advances in the Multidisciplinary Care of Patients with Tenosynovial Giant Cell Tumor on a virtual platform by Spire Learning.
    • July 7, 2021 Lete-cel Regional Steering Committee member of GlaxoSmithKline
    • Nov 7, 2021 Caris Life Sciences Advisory panel meeting
    • March, 26,2022 Sarcoma therapy BioAlas Advisory panel meeting
  • Speaker’s Bureau:
    • Feb 2, 2021 Merck
    • May 14-15 Osler Review Anatomic Pathology virtual slide review (bone and cytopathology)

All of the relevant financial relationships listed for this individual have been mitigated (planner and moderator).


Justin Bishop, MD - Has nothing to disclose.

Kamran M. Mirza, MD PhD - Has nothing to disclose.

Susan Boisvert BSN, MHSA, DFASHRM - Has nothing to disclose.

Peter A. Humphrey, MD, PhD All of the relevant financial relationships listed for this individual have been mitigated.

  • Consultant/Advisor/Contractor: Ibex Medical Analytics, Johnson and Johnson

Victor G. Prieto, MD, PhD All of the relevant financial relationships listed for this individual have been mitigated.

  • Consultant/Advisor/Contractor: Honorarium (Castle, Merck, Orlucent)




It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA’s approval of course content for AMA PRA Category 1 Credits™. does not constitute an endorsement of the ideas, positions or statements contained therein. Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.


Please join us at the FSP 2023 Summer Pathology Conference taking place on July 14-16, 2023 at the Eau Palm Beach Resort & Spa.  Exhibitors will connect with 100-150 pathologists during the conference as well as engage in over 15 hours of face to face time with attendees.
Other benefits include:

  • Pre and post attendee lists.
  • Benefit from listings on onsite signage, virtual exhibit hall and the FSP onsite guide.
  • Gain maximum exposure with prize giveaways and breaks scheduled in the exhibit hall.
  • Receive between 2-6 complimentary badges to access the exhibit hall dependent on sponsorship level chosen.

The exhibit hall is now sold out. If you would like to be added to the wait list please contact exhibits@flpath.org

View/Download Prospectus

Satellite Events


Special Events


Confirmed Exhibitors


Thank you to the following companies for their support of the FSP 2023 Summer Pathology Conference:



Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.


APS Medical Billing is a premier billing firm that provides expert billing and practice management solutions to pathology and laboratory practices nationwide. APS’ clients range in size from a single-physician practice to large, multi-site academic departments, reference and independent labs. The scope of our billing services and proven strategies allow APS to effectively bill for professional, technical and global components of anatomic and clinical pathology services. Please visit our website at www.apsmedbill.com.

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.


Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).


Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. (www.CastleTestInfo.com)


Cleveland Clinic Laboratories is a full-service, national reference laboratory dedicated to providing world-class care. Our laboratories offer high-quality, clinically impactful pathology and laboratory diagnostics services combined with readily available consultation from experienced pathologists and laboratory scientists.


Daiichi Sankyo is a pharmaceutical company focused on ADC's in lung, GI, and breast cancer. 

We are pioneers in diagnostic kits for advanced DNA testing. Our goal is to eliminate tedious protocols and streamline laboratory workflows with simple, fast, and accurate genetic testing solutions. Together we can make personalized healthcare available to all patients – for a correct diagnosis and faster treatment.

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

At HCA Healthcare, we are driven by a single mission: Above all else, we are committed to the care and improvement of human life.

HCA Healthcare is dedicated to giving people a healthier tomorrow. As one of the nation's leading providers of healthcare services, HCA Healthcare is comprised of 182 hospitals and 2,300+ sites of care in 20 states and the United Kingdom.In addition to hospitals, sites of care include surgery centers, freestanding ERs, urgent care centers, diagnostic and imaging centers, walk-in clinics and physician clinics.


At Innovative Science Press, we are dedicated to the advacment of pathologists by producing and disseminating educational textbooks. We believe that all pathologists deserve access to quality and affordable medical training in order to help their patients. For this reason, our books are written by some of the most prominent in the field and are reasonably priced. We provide steep discounts to residents and fellows to make our products more affordable and donate frequently to the under-served countries.

Molecular diagnostic testing for indeterminate thyroid nodules utilizing multi platform testing. ThyGeNEXT is an oncogenic mutation panel that helps identify malignant thyroid nodules and ThyraMIR is a proprietary microRNA gene expression assay that helps to clarify the risk of cancer in thyroid nodules.



Specialty diagnostics at every stage of cancer care. We help you navigate the complex treatment landscape, connecting insights from patients, trials, health systems and managed care partners to power decisions that improve patient outcomes.

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.



MedReceivables Advisor, LLC is a full service outsourcing medical billing company for the hospital based physician. Our company provides complete accounts receivable management services for hospital-based physicians.

Milestone's innovative products range from specimen collection, to processing, to embedding, and further, including many steps in between. Milestone's mission is to reduce patient anxiety by standardizing and expediting the pre-analytical steps of the histopathology lab and the operating room specimen collection and transportation. In doing so, our goal is to enable superior quality, same-day diagnoses.  Milestone is proud to offer innovative solutions in 6 different fields:  Tissue Processing, Specimen Handling, Frozen sections, Cytology, Macro Digital and Reagents.  See what we have to offer: https://www.milestonemed.com


MSN's Pathology Solutions Team has over 20 years of pathology billing experience working with hospital-based practices and outreach facilities.  We balance the skills and understanding of our expert billing staff with excellent technology,a combination resulting in diligent claims follow-up and collection activity for our pathology clients.  MSN is passionate about client service, and we build strong partnerships with the pathology groups we serve.  We are dedicated to becoming one of the leading pathology billing companies in the country.


DNA is in our blood.
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.


NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore. 


We provide private autopsies for families looking for answers after the passing of a loved one in Natural death cases. Our pathologist is a board certified pathologist specializing in anatomic pathology. We offer a full comprehensive exam trying to find cause of death, any contributing factors as well as any underlying disease. In cases where dementia is present, we can provide confirmation of Alzheimer’s disease. We also do toxicology screening, cultures for infections present and covid swab when necessary. Our goal is to provide answers for families and closure.


Big thinking for people with rare diseases
Everything we do is driven by the needs of people who have a rare disease:

Our team believes that each person with a rare disease has the right to the best treatment.
We have nearly 30 years' experience in bringing orphan drugs to market for rare diseases, with a portfolio of 18 products and a significant research and development program.
We help to develop, and work alongside, global networks of patients, patient groups, experts, healthcare professionals, scientists, policy makers and regulators.
We employ professionals in over 30 countries, and are rapidly expanding globally.
We have unparalleled experience in the development of clinical trials for orphan drugs and in specialist regulatory requirements.
Our infrastructure has been developed to uniquely produce, package and distribute very small to high numbers of specialist products worldwide.
Recordati Rare Diseases is committed to improving the diagnosis and management of rare diseases through our educational work and the Recordati Rare Diseases Foundation.


Roche Indy is the North American headquarters of the world's largest biotech company, where more than 4,000 people work together to provide insights that help people around the world manage and improve personal health conditions. We lead the industry in the development of diagnostics products for cancer, cardiac health, infectious diseases, women's health and in diabetes management. Diagnostics informs 70 percent of clinical decisions, including the prevention, identification and treatment of diseases, and are a critical part of modern medicine as care becomes more personalized.

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We're driven by a singular mission to make a difference for people impacted by cancer.  
As an industry leader in antibody drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology. We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.


SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines. We do it to help patients suffering from devastating cancers live longer, better lives.

How? We scrutinize promising molecules from every angle to unlock their full potential. We forge collaborations with industry and academic innovators to multiply the opportunities for success. And we build our company with exceptional people who press beyond “good enough” to make a profound impact. In a word, we are tenacious.

Are you with us?



The University of Miami Health System delivers leading-edge patient care by the region's best doctors, powered by the groundbreaking research and medical education of the University of Miami Leonard M. Miller School of Medicine. As South Florida's only university system, UHealth is a vital component of the community.

UHealth combines patient care, research, and education to create a front-line approach to health care. Within the UHealth system, patients can participate in clinical trials and benefit from the latest developments that are fast-tracked from the laboratory to the bedside.


Coming soon


Networking Events




Confirmed Sponsors

Coming soon

Rare and Interesting Case Competition